Beta Drugs Launches ‘Adsunib' the First Indian Brand of Sunitinib

Beta Drugs, a leading manufacturer of oncology products, announces the launch of Adsunib brand of Sunitinib.
Adsunib is the first branded generic of Sunitinib with all dosage strength of 12.5/25/50 mg capsules, used for the treatment of Renal Cell Carcinoma (RCC), Gastro-Intestinal Tumor (GIST) & Pancreatic Neuroendocrine Tumor (pNET).

Adsunib greatly reduces the monthly therapy cost of Sunitinib. It will significantly impact the lives of cancer patients who have thus far been denied access to this drug due to the high cost.

Apart from Sunitinib, the company was the first to launch Axitinib and Lenvatinib that strengthens the company’s portfolio in Renal Cell Carcinoma therapy thus establishing it as a market leader in branded Oncology products.

Recently, the company also launched ‘Adleap’ brand of Enzalutamide used for the treatment of prostate cancer which is the most economical brand in India. The lower financial burden will aid adherence.

The company is poised for robust growth. It is strengthening its Oncology portfolio by in-house development of new products like Tyrosine Kinase Inhibitors (TKIs) and improving existing products through New Drug Delivery System (NDDS) that will help to bridge the unmet need of cancer patients. The company has the vision to launch 28 new products in the next 3 years.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types